Optima Capital’s Acrivon Therapeutics ACRV Stock Holding History

Optima Capital’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-278	Closed	-$670	–	170
2025 Q4	$670	Buy	+278	New	+$604	﹤0.01%	1039

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Optima Capital's ACRV Position: Q1 2026 in Review

Optima Capital sold out of Acrivon Therapeutics (ACRV) in Q1 2026, closing a stake of 278 shares — an estimated $670 sold.

Optima Capital first reported a position in ACRV in Q4 2025 and held it in 1 quarter. The position peaked at $670 in Q4 2025. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

Optima Capital reported no remaining Acrivon Therapeutics position as of Q1 2026 after selling out during the quarter.
Optima Capital sold 278 Acrivon Therapeutics shares in Q1 2026, an estimated $670.
Optima Capital first reported a position in Acrivon Therapeutics in Q4 2025 and held it in 1 quarter.
Optima Capital's Acrivon Therapeutics position peaked at $670 in Q4 2025.
44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on Optima Capital's 13F filing for Q1 2026, filed 5 May 2026.